Qbrelis Patent Expiration

QBRELIS IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039800 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US9616096 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US10265370 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US9463183 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US11179434 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US9814751 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US10940177 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US11771733 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US10406199 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)



Qbrelis is a drug owned by Azurity Pharmaceuticals Inc. It is used for treating acute myocardial infarction, hypertension, and heart failure. Qbrelis uses Lisinopril as an active ingredient. Qbrelis was launched by Azurity in 2016. It is is available in solution form for oral use. Its generic launch date based on the expiry of its last outstanding patent is estimated to be Nov 06, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using LISINOPRIL ingredient

Market Authorisation Date: 29 July, 2016

Treatment: Method of treating hypertension; Method of treatment of heart failure; Acute myocardial infarction

Dosage: SOLUTION

How can I launch a generic of QBRELIS before it's drug patent expiration?
More Information on Dosage

QBRELIS family patents

Family Patents